University of Louisville homepage
All experts
All experts

Abigail Stocker

Assoc Professor Term

School of Medicine

  • Assoc Professor Term
    School of Medicine

SPONSORED PROJECTS

  • Showing page 1 out of 2
Showing page 1, sponsored projects 1 to 25 of 31
GRANT
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adult Subjects with Idiopathic Gastroparesis
CinDome Pharma Inc_CPI1 Jan 2025
MORELEARN MORE
GRANT
231108|VP-VLY-686-3303 - Single-Patient Expanded Access Protocol for Tradipitant in a Single Patient with Gastroparesis
Vanda Pharmaceuticals_VANDA3 Jul 2024 - 3 Jul 2027
MORELEARN MORE
GRANT
240510|EXPEDITE Examination of Programming with the Enterra Therapy System in a Double-Blinded, Randomized, Prospective Study In the Treatment of Nausea and Vomiting Symptoms Using Gastric Electrical Stimulation
Enterra Medical Inc_ENTERRA18 Mar 2024 - 30 Jun 2027
MORELEARN MORE
GRANT
250387|ENT-CL-5000 - A Prospective Randomized Controlled Trial of Chronic Nausea and Vomiting in Patients with Normal Gastric Emptying using the Enterra Therapy System (NAVIGATE)
Enterra Medical Inc_ENTERRA1 Jan 2024 - 10 Sep 2027
MORELEARN MORE
GRANT
230897|RESTING -Randomized Study of Enterra Programming with Nocturnal Cycling in Gastroparetics (CLN 001-PR-00755)
Enterra Medical Inc_ENTERRA7 Oct 2023 - 31 Dec 2030
MORELEARN MORE
GRANT
230754|CIN-102-123 - A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacokinetics of Oral CIN-102 in Subjects with Diabetic Gastroparesis
Medpace Inc_MPI1 Jan 2023
MORELEARN MORE
GRANT
230758|A0015 - Comparison of the Atmo Motility Gas Capsule System to the reference standard (SmartPill) for gastrointestinal transit time measures in patients with functional gastrointestinal symptoms and dysmotility
Atmo Biosciences Pty Limited_ATMOBIOS1 Jan 2023
MORELEARN MORE
GRANT
211055C|U of L Clinical Center to Investigate the Pathogenesis, Etiology, and Treatment of Gastroparesis through the NIDDK Gastroparesis Consortium
NIH National Institutes of Health_NIH (SPN-000205)9 Jan 2022 - 31 Dec 2027
MORELEARN MORE
GRANT
211055D|UofL Clinical Center to Investigate the Pathogenesis, Etiology, and Treatment of Gastroparesis through the NIDDK Gastroparesis Consortium
NIH National Institutes of Health_NIH (SPN-000205)9 Jan 2022 - 31 Dec 2027
MORELEARN MORE
GRANT
211055|U of L Clinical Center to Investigate the Pathogenesis, Etiology, and Treatment of Gastroparesis through the NIDDK Gastroparesis Consortium
National Institutes of Health_NIH9 Jan 2022
MORELEARN MORE
GRANT
220823|PCS12852-GP-01 -A Phase 2A PC, R, Dose Response Study of the Safety, Pharmacokinetics and Efficacy of PCS12852 on Gastric Emptying Rate Assessed by 13C Spirulina GEBT in Pts w Moderate to Severe Gastroparesis
Medpace Inc_MPI1 Jan 2022
MORELEARN MORE
GRANT
200412|0164-A 3-Year, Multi-Center, Long-Term Safety (LTS) Study to Evaluate the Safety and Tolerability of TD-1473 in Subjects with Ulcerative Colitis (UC)
Theravance Inc_THERAVANCE2 Dec 2020
MORELEARN MORE
GRANT
201078|MDGN-002-CD-101 Ph Ib Esc Dose, OL, Signal-Findng Sty Eval Sfty, Tolerab, Short-Trm Eff Anti-Light Monoclonal Antibod MDGN-002 in Adults w Mod to Severe Active Crohn?s Dis, Failed Prior Trtmnt Anti-TNF Agent, w/wo Loss of Fnctn Mutatn in Decoy Receptor 3
Aevi Genomic Medicine Inc_AGMINC5 Jan 2020
MORELEARN MORE
GRANT
210394|NG101-201 - A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of NG101 Administered Orally to Patients with Gastroparesis
PPD Clinical Research_PCR1 Jan 2020
MORELEARN MORE
GRANT
200048|VLY-686-3301 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Assess The Efficacy of Tradipitant in Relieving Symptoms of Gastroparesis
Vanda Pharmaceuticals_VANDA10 Nov 2019
MORELEARN MORE
GRANT
180438|0173 A Phase 2 Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Induction Therapy with 2 Doses of TD-1473 in Subjects with Moderately-to-Severely Active Crohn's Disease
PRA Health Sciences Inc_PRA1 Jan 2019
MORELEARN MORE
GRANT
190326|3071-305-020 Allergan Relamorelin Diabetic
Allergan Inc_ALL1 Jan 2019
MORELEARN MORE
GRANT
191139|Theravance PRA 0157 UC Efficacy and Safety of TD-1473
PRA Health Sciences Inc_PRA1 Jan 2019
MORELEARN MORE
GRANT
200093|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Dose Response of Oral CIN-102 in adults with Diabetic Gastroparesis
Medpace Inc_MPI1 Jan 2019
MORELEARN MORE
GRANT
180784|CNT01275CRD3007 A Phase 3b, Multicenter, Randomized, Blinded, Active-Controlled Study to Compare the Efficacy and Safety of Ustekinumab to Adalimumab in the Treatment of Biologic Naive Subjects with Moderately to Severely Active Crohn's Disease
Janssen Research and Development_JRAD8 Jul 2018
MORELEARN MORE
GRANT
170152|Vedolizumab-4006 An OL,Ph 4 Study to Evaluate the Efficacy & Safety of Triple Combination Therapy w Vedolizumab IV, Adalimumab SC, & Oral Methotrexate in Early Treatment of Subjects w Crohn's Disease Stratified at Higher Risk for Developing Complications
Robarts Clinical Trials Inc_RCT1 Jan 2018
MORELEARN MORE
GRANT
180456|M14-431 A MC, Randomized, D-B, Placebo-Controlled Induction Study of the Efficacy & Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely active Crohn's Disease Who Have Inadequately Responded to or are Intolerant to Biologic Therapy
AbbVie Inc_ABBVI1 Jan 2018
MORELEARN MORE
GRANT
180457|M14-433 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in subjects with Crohn's Disease who Completed the Studies M14-431 or M14-433
AbbVie Inc_ABBVI1 Jan 2018
MORELEARN MORE
GRANT
180640|RLM-MD-04 A 52-week, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Gastroparesis
Allergan Inc_ALL1 Jan 2018
MORELEARN MORE
GRANT
190207|M14-430 A Multicenter, Randomized, Double Blind, Placebo-Controlled Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Crohn's Disease who Completed the Studies M14-431 or M14-433
AbbVie Inc_ABBVI1 Jan 2018 - 31 Dec 2027
MORELEARN MORE